Torrent Pharmaceuticals Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company indicates that by FY’26, it expects to be net cash positive. - Capital allocation going forward will depend on EBITDA and cash flow generation. - Acquisitions remain an integral part of the growth strategy, pursued within financial frameworks aimed at creating long-term shareholder value. - No specific plans for raising new capital via debt or equity were disclosed during the call.

- The company continues to pursue acquisitions as an integral part of its growth strategy, focusing on creating long-term shareholder value. - Acquisition formats include business transfers through slump sales and company acquisitions (e.g., Curatio was a recent company acquisition). - All combinations for acquisitions are open, with a preference for acquiring 100% stakes. - Interest lies in both branded assets and good generic assets. - Focus is on existing markets like Brazil, Mexico, and potentially new markets. - No specific inorganic investment figures or timelines were provided. - R&D spend is steady at around 5% of revenues, with no material change expected for the full year. - Capital allocation is expected to be tied to cash flow and EBITDA generation, with FY'26 anticipated to be net cash positive. (Source: Pages 5, 6, 7, 8, 12, and 13)

- India business: Expecting low teens growth going forward, with Q1 at 15%, driven by 2.5% volume, 8.5% price, and 4% new products. Chronic segment growth remains sustainable (~13%+). - Cardiac portfolio: Losar brand expected to slip to #3 next year; growth driven by 4-5 other strong cardiac brands in future growth markets. No significant new cardiac launches anticipated soon; growth from existing brands. - US business: Targeting 5-10 product approvals this year, including oncology and diversified therapies; profitability expected post-R&D over next 2-3 years as launches ramp up. - Brazil: Underlying growth rate of 12-13% (constant currency), with 3-6 product launches annually and 19 molecules pending approval. - Germany: Mid-to-high single digits growth expected, driven by winning new tenders. - Consumer health: Key brands like Shelcal growing high teens; overall consumer segment growth supported by sustained A&P spend. Overall, growth driven by portfolio derisking, new launches, market share gains, and expansion in key regions.

- US Business: Expected to turn profitable post-R&D over the next 2-3 years driven by new product launches, including 5-10 approvals targeting oncology and other diversified therapies. (Page 12) - India Business: Sustained strong growth with 15% growth in Q1 and a guided low teens growth rate for key products like Unienzyme and Vizylac. Chronic portfolio expected to grow 1-2% sustainably due to de-risking strategies. (Pages 4, 6, 10, 12) - Brazil Business: Underlying constant currency growth expected around 12-13% with 3-6 launches planned per year, partially offset by currency fluctuations but overall profitability impact minimal. (Pages 3, 11) - Germany Business: Mid-to-high single digit growth expected driven by new incremental tenders and improved cost competitiveness. (Page 6) - Margins: Full-year margin expansion of 50-100 bps expected with gross margins around 75% sustainable. (Pages 4, 11) - Overall, Torrent aims for profitable growth with EBITDA margin at 32.3%, net debt-to-EBITDA at 0.65, and consistent cash flow generation to fund acquisitions and growth. (Pages 2, 4)

The provided document (page 13 and related Q&A) does not explicitly mention or provide details about the current or expected orderbook or pending orders for Torrent Pharma Limited. The discussion mainly focuses on business performance, product launches, market strategies, and regulatory updates without specific data on orderbook status. If you need orderbook or pending order information, it might be available in other sections of the company’s reports or investor presentations not included here.